The Molecular Basis of Cancer and the Development of Targeted Therapy

Surgical Clinics of North America

Volumn 89, Issue 1, 2009, Pages 1-15

  Riley, Lee B ^a   Desai, Darius C ^a  

^a ST LUKE S HOSPITAL   (United States)

Author keywords

Breast tumor suppressor; Epigenetic; Genomic oncogenes; Molecular; Targeted

Indexed keywords

APC PROTEIN; BEVACIZUMAB; CETUXIMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENDOTHELIAL CELL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; LAPATINIB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLATELET DERIVED GROWTH FACTOR; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STEM CELL FACTOR; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

ADENOMATOUS POLYP; ADJUVANT THERAPY; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STEM CELL; CANCER SURGERY; CELL IMMORTALIZATION; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DNA MICROARRAY; DNA REPAIR; DRUG RECEPTOR BINDING; DRUG TARGETING; EPIGENETICS; GASTROINTESTINAL STROMAL TUMOR; GENE FUNCTION; GENETIC SCREENING; GENOMIC INSTABILITY; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HORMONAL THERAPY; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MASTECTOMY; MELANOMA; METASTASIS; MOLECULAR BIOLOGY; NEOPLASM; ONCOGENE; ONCOLOGY; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RASH; REVIEW; SURGEON; THROMBOSIS; THYROID MEDULLARY CARCINOMA; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; WOUND HEALING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; DNA REPAIR; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; PHENOTYPE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58749084711     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2008.09.016     Document Type: Review

References (74)

1. McPherson J.D., Marra M., Hillier L., et al. A physical map of the human genome. Nature 409 6822 (2001) 934-941
2. Venter J.C., Adams M.D., Myers E.W., et al. The sequence of the human genome. Science 291 5507 (2001) 1304-1351
3. Palacios J., Robles-Frias M.J., Castilla M.A., et al. The molecular pathology of hereditary breast cancer. Pathobiology 75 2 (2008) 85-94
4. Abdel-Rahman W.M., Mecklin J.P., and Peltomaki P. The genetics of HNPCC: application to diagnosis and screening. Crit Rev Oncol Hematol 58 3 (2006) 208-220
5. Galiatsatos P., and Foulkes W.D. Familial adenomatous polyposis. Am J Gastroenterol 101 2 (2006) 385-398
6. Dionigi G., Bianchi V., Rovera F., et al. Medullary thyroid carcinoma: surgical treatment advances. Expert Rev Anticancer Ther 7 6 (2007) 877-885
7. Goldenberg D.M., Chatal J.F., Barbet J., et al. Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther 2 1 (2007) 19-31
8. Olafsen T., Tan G.J., Cheung C.W., et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 17 4 (2004) 315-323
9. Sundaresan G., Yazaki P.J., Shively J.E., et al. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 44 12 (2003) 1962-1969
10. Dehdashti F., Picus J., Michalski J.M., et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 32 3 (2005) 344-350
11. Peterson L.M., Mankoff D.A., Lawton T., et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 49 3 (2008) 367-374
12. Virtanen C., and Woodgett J. Clinical uses of microarrays in cancer research. Methods Mol Med 141 (2008) 87-113
13. Golub T.R., Slonim D.K., Tamayo P., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286 5439 (1999) 531-537
14. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 406 6797 (2000) 747-752
15. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 27 (2004) 2817-2826
16. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100 14 (2003) 8418-8423
17. Henshall S.M., Afar D.E., Hiller J., et al. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 63 14 (2003) 4196-4203
18. Potti A., Mukherjee S., Petersen R., et al. A genomic strategy to refine prognosis in early-stage nonsmall cell lung cancer. N Engl J Med 355 6 (2006) 570-580
19. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25 33 (2007) 5287-5312
20. zur Hausen H. Viruses in human cancers. Eur J Cancer 35 14 (1999) 1878-1885
21. Bishop J.M. Cellular oncogenes and retroviruses. Annu Rev Biochem 52 (1983) 301-354
22. Alitalo K., and Schwab M. Oncogene amplification in tumor cells. Adv Cancer Res 47 (1986) 235-281
23. Land H., Parada L.F., and Weinberg R.A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304 5927 (1983) 596-602
24. Vogelstein B., and Kinzler K.W. The multistep nature of cancer. Trends Genet 9 4 (1993) 138-141
25. Harris H. Cell fusion and the analysis of malignancy: the Croonian lecture. Proc Royal Soc London B Biol Sci 179 (1987) 1
26. Knudson Jr. A.G. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68 4 (1971) 820-823
27. Weinberg R.A. Cancer: a genetic disorder. In: Mendelsohn J., Howley P., Israel M., et al. (Eds). The molecular basis of cancer (2008), Saunders, Phildelphia 3-17
28. Charames G.S., and Bapat B. Genomic instability and cancer. Curr Mol Med 3 7 (2003) 589-596
29. D'Andrea A. DNA repair pathways and human cancer. In: Mendelsohn J., Howley P., Israel M., et al. (Eds). The molecular basis of cancer (2008), Saunders, Philadelphia 39-57
30. Cleaver J.E. Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat Rev Cancer 5 7 (2005) 564-573
31. Heinen C.D., Schmutte C., and Fishel R. DNA repair and tumorigenesis: lessons from hereditary cancer syndromes. Cancer Biol Ther 1 5 (2002) 477-485
32. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 8 10 (2007) 735-748
33. Cong Y., and Shay J.W. Actions of human telomerase beyond telomeres. Cell Res 18 7 (2008) 725-732
34. De Lange T. Telomere-related genome instability in cancer. Cold Spring Harb Symp Quant Biol 70 (2005) 197-204
35. Hahn W.C., and Meyerson M. Telomerase activation, cellular immortalization and cancer. Ann Med 33 2 (2001) 123-129
36. Baylin S.B., and Herman J.G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16 4 (2000) 168-174
37. Yang J., and Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14 6 (2008) 818-829
38. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2 6 (2002) 442-454
39. Goh P.P., Sze D.M., and Roufogalis B.D. Molecular and cellular regulators of cancer angiogenesis. Curr Cancer Drug Targets 7 8 (2007) 743-758
40. Zureikat A.H., and McKee M.D. Targeted therapy for solid tumors: current status. Surg Oncol Clin N Am 17 2 (2008) 279-301
41. Grandis J.R., and Sok J.C. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102 1 (2004) 37-46
42. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7 Suppl 4 (2002) 2-8
43. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59 8 (1999) 1935-1940
44. Nait W., Rubin E., and Bertino J. Cancer therapeutics. In: Mendelsohn J., Howley P., Israel M., et al. (Eds). The molecular basis of cancer (2008), Saunders, Philadelphia 571-582
45. Yang X.D., Jia X.C., Corvalan J.R., et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38 1 (2001) 17-23
46. Folkman J. Angiogenesis. Annu Rev Med 57 (2006) 1-18
47. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9 Suppl 1 (2004) 2-10
48. Presta L.G., Chen H., O'Connor S.J., et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57 20 (1997) 4593-4599
49. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 2 (2004) 145-147
50. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 19 (2004) 7099-7109
51. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 57 1 (2007) 43-66
52. Fernando N.H., and Hurwitz H.I. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 9 Suppl 1 (2004) 11-18
53. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 1 (2003) 60-65
54. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004) 2335-2342
55. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 4 (2004) 337-345
56. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 4785 (1987) 177-182
57. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 9 (1999) 2639-2648
58. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
59. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 16 (2005) 1673-1684
60. Michaud D.S. Epidemiology of pancreatic cancer. Minerva Chir 59 2 (2004) 99-111
61. Burris III H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 6 (1997) 2403-2413
62. Diaz-Rubio E. New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist 9 3 (2004) 282-294
63. MacKenzie M.J. Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol 5 9 (2004) 541-549
64. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 15 (2007) 1960-1966
65. Rubin B.P., Singer S., Tsao C., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61 22 (2001) 8118-8121
66. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 7 (2002) 472-480
67. Institute NC. A phase III randomized double-blind study of adjuvant imatinib mesylate (Gleevec; STI571) versus placebo in patients following the resection of primary gastrointestinal stomal tumors (GIST). ACOSOG-Z9001. Available at:. http://www.cancer.gov/clinicaltrials/ACOSOG-Z9001
68. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 9544 (2006) 1329-1338
69. Llovet J., Ricci S., and V M. For the SHARP investigators study group. Sorafenib improves survival in advanced heaptocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 25 Suppl 18S (2007) LBA1
70. Mimeault M., Hauke R., Mehta P.P., et al. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 11 5 (2007) 981-1011
71. Buchstaller J., Quintana E., and Morrison S. Cancer stem cells. In: Mendelsohn J., Howley P., and Israel M. (Eds). The molecular basis of cancer (2008), Saunders, Philadelphia 141-154
72. Bao S., Wu Q., McLendon R.E., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 7120 (2006) 756-760
73. Hermann P.C., Huber S.L., Herrler T., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1 3 (2007) 313-323
74. Yilmaz O.H., Valdez R., Theisen B.K., et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441 7092 (2006) 475-482